MYO2

MYO2 is a preclinical small molecule drug candidate developed by Myocea for the treatment of Spinal Muscular Atrophy (SMA). It was identified through Myocea's proprietary screening platform, which utilizes Satellite-like Cells (SLCs) to discover compounds that modulate skeletal muscle and neuromuscular junction (NMJ) biology. MYO2 is designed to target a specific biological pathway referred to as Network 2 to address the muscle-specific components of SMA pathology. This approach aims to provide therapeutic benefit by directly targeting the skeletal muscle and NMJ defects associated with the disease, potentially serving as a complementary therapy to existing SMN-upregulating treatments.

Other names

Myocea-Network 2-small molecule-Spinal Muscular Atrophy (SMA)Network 2 SMA small moleculeNetwork2 SMA small moleculeNetwork-2 SMA small molecule